Why the study?
This study aimed to reduce the risk of cardiovascular incidents and radiation pneumonia by improving dose distribution to cardiac substructures using a dual-layer multileaf collimator accelerator.
Does a dual-layer multileaf collimator (MLC) system improve dosimetric sparing of cardiac substructures and reduce modeled cardiovascular risks in patients with locally advanced lung cancer compared to a single-layer MLC system?
Does a dual-layer multileaf collimator (MLC) system improve dosimetric sparing of cardiac substructures and reduce modeled cardiovascular risks in patients with locally advanced lung cancer compared to a single-layer MLC system?
A dual-layer multileaf collimator system for lung cancer radiotherapy achieves superior dosimetric sparing of cardiac substructures compared to standard single-layer systems, potentially reducing the risk of major adverse cardiac events.
Answers are grounded in this paper and cite their sources.
May improve cardiac substructure sparing in lung RT; leaves open clinical outcome benefit.
Purpose: This study aims to reduce the risk of cardiovascular incidents and radiation pneumonia (RP) by improving the dose distribution to cardiac substructures through the use of a dual-layer multileaf collimator (MLC) accelerator- VenusX. Methods and Materials: Eighteen patients with advanced-stage lung cancer were selected for this study. The total lung, spinal cord, whole heart, and specific cardiac substructures (including the left ventricle [LV], pulmonary artery, left anterior descending artery, left circumflex artery [LCX], and coronary artery) were delineated as organs at risk and incorporated into the optimization process of the avoidance plan. Single-layer MLC plans optimized for the whole heart, referred to as S-WH plans (where WH denotes whole heart), were developed alongside single-layer MLC plans specifically designed to avoid cardiac substructures, known as S-CS plans (where CS denotes cardiac substructures). Additionally, dual-layer MLC avoidance plans, designated as D-CS plans, were created for each patient. We evaluated the relative risk of coronary artery disease, chronic heart failure, acute cardiac events, and RP, as well as the effective dose to the immune system. Results: of LCX, with other substructures also experiencing a notable degree of dose reduction. Furthermore, the relative risk of coronary artery disease, chronic heart failure, acute cardiac event, and RP is ranked as follows: D-CS < S-CS < S-WH plans. Effective dose to the immune system of the D-CS plans indicated the lowest risk among the 3 plans. Conclusions: The dual-layer MLC system demonstrated superior performance compared to the single-layer MLC system in CS-avoidance plans, providing new opportunities for subsequent immunotherapy in patients with locally advanced lung cancer.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: